Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Abstract Venetoclax (VEN) combined with azacitidine (AZA) or low-dose cytarabine (LDAC) has significantly improved outcomes for older patients with acute myeloid leukemia (AML). However, severe cytopenia often leads to treatment interruptions. Previous literature has reported…
Key Points Frontline eltrombopag plus IST is cost-effective compared with IST alone for adults with severe aplastic anemia. Incremental net monetary benefit per patient treated with frontline eltrombopag is ∼$64 000. Abstract The randomized phase 3 RACE trial demonstrated…
In this issue of Blood, Muffly et al1 demonstrate in a phase 1 trial the feasibility and safety of CD117-targeted, precision preconditioning for allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) and myelodysplastic neoplasia (MDS). Almost 70…
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Key Points Chromosome 5q deletion drives progressive chromosome evolution in TP53-mutant preleukemic HSPCs. Aneuploid HSPCs exhibit a shared gene expression signature which confers unique therapeutic vulnerabilities in AML-CK. Clonal acquisition of multiple chromosomal…
On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy…
Abstract Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). While genetic alterations can contribute to resistance, the role of rapid-adaptive non-genetic mechanisms, particularly transcription…
Key Takeaways Approval targets older/unfit newly diagnosed AML, introducing an all-oral HMA/venetoclax backbone that may reduce infusion burden and expand outpatient feasibility. ASCERTAIN‑V part B delivered DEC‑C days 1–5 q28d with venetoclax ramp-up to 400 mg then 400 mg daily…
ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…
Abstract The Dedicator of Cytokinesis1 (DOCK1) has been implicated in solid tumors; however, its precise role and therapeutic potential in acute myeloid leukemia (AML) remain largely unexplored. Here we investigated the prognostic significance and functional roles of DOCK1 in AML…